Regennova, Inc.
Durham, NC
- UEI
- K9VQL9BKC1A9
- CAGE
- 8X9J5
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 3326 Durham-Chapel Hill Blvd #100E, Durham, NC 27707, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Arginine-polyamine pathway inhibitor for treatment of adpkd - our overarching goal is to develop an orally-available,… | National Institute of Diabetes and Digestive and Kidney Diseases | $688,494 | |
| A therapeutic role for apolipoprotein-e in the germ theory of alzheimer's dementia - abstract: a therapeutic role for… | National Institute on Aging | $500,000 | |
| Therapeutic reduction of cerebral amyloid angiopathy pathologies in adrd - abstract: therapeutic reduction of cerebral… | National Institute of Neurological Disorders and Stroke | $999,800 |
About Regennova, Inc.
Regennova, Inc. is a corporate entity located in Durham, North Carolina, registered in SAM.gov and classified as a self-certified small disadvantaged business. The company appears to be focused on biomedical research and drug development, with a particular emphasis on developing therapeutic interventions for complex medical conditions. While specific details about the company's full background are not provided, the federal grant award history suggests Regennova is actively engaged in innovative medical research targeting challenging diseases.
Regennova, Inc. has received multiple federal grant awards from the National Institute of Aging and the National Institute of Diabetes and Digestive and Kidney Diseases, focusing on advanced medical research in neurodegenerative and kidney diseases. The company's research portfolio includes developing therapeutic strategies for autosomal dominant polycystic kidney disease (ADPKD), investigating the relationship between Porphyromonas gingivalis and Alzheimer's dementia, and exploring potential treatments for cerebral amyloid angiopathy. Specifically, the company has been awarded project grants totaling approximately $349,325 for ADPKD research, with work targeting the arginine-polyamine pathway to potentially reduce cyst growth and improve kidney function. Additionally, Regennova has conducted research on apolipoprotein-E mimetics to address neurological conditions, including developing strategies to combat P. gingivalis bacteria and reduce neuroinflammation associated with Alzheimer's disease and related dementias.
Quick answers
What is Regennova, Inc.'s UEI?
Regennova, Inc.'s Unique Entity ID (UEI) in SAM.gov is K9VQL9BKC1A9.
What is Regennova, Inc.'s CAGE code?
Regennova, Inc.'s CAGE code is 8X9J5.
What is Regennova, Inc.'s primary NAICS code?
Regennova, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Regennova, Inc. located?
Regennova, Inc.'s physical address in SAM.gov is 3326 Durham-Chapel Hill Blvd #100E, Durham, NC 27707, USA.
Is Regennova, Inc. registered in SAM.gov?
Yes. Regennova, Inc.'s SAM.gov registration is active through March 3, 2027.
What is Regennova, Inc.'s most recent federal award?
Regennova, Inc.'s most recent federal grant award is Arginine-polyamine pathway inhibitor for treatment of adpkd - our overarching goal is to develop an orally-available,… (R44DK141418), from National Institute of Diabetes and Digestive and Kidney Diseases, on August 1, 2025.
On GovTribe
See Regennova, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors